Skip to main content

Table 1 Baseline characteristics of children suffering from acute uncomplicated malaria treated with artemether–lumefantrine or pyronaridine–artesunate in Ibadan SW Nigeria

From: Efficacy and safety of pyronaridine–artesunate versus artemether–lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial

Characteristics

Drug group

Total

ρ-value

AL

PA

Sex

    

 Male

45 (50.0%)

45 (50.0)

90 (100)

0.880

 Female

42 (51.2%)

40 (48.8%)

82 (100)

Age (months)

    

 Mean ± SD

79.93 ± 37.16

82.39 ± 38.63

81.15 ± 39.80

0.671

 Range

8–144

4–143

4–144

 3–11 months

3 (3.5)

5 (5.9)

8 (4.7)

0.703

 12–59 months

20 (23.0)

21 (24.7)

41 (23.8)

 ≥ 60 months

64 (73.6)

59 (69.4)

123 (71.5)

Weight (kg)

    

 Mean ± SD

18.59 ± 6.49

18.67 ± 6.74

18.63 ± 6.59

0.938

 Range

7.0–36.0

5.5–40.0

5.5–40

Temperature (°C)

    

 Mean ± SD

37.7 ± 1.06

37.4 ± 1.07

37.6 ± 1.08

0.074

 Range

35.1–40.2

35.9–39.9

35.1–40.2

Parasite density (/µl)

    

 Geomean

32,755

28,211

30,424

0.815

 Range

1035–758,958

1600–1,652,505

1035–1,652,505

Haematocrit (%)

    

 Mean ± SD

32.14 ± 5.06

32.14 ± 5.48

32.14 ± 5.26

0.997

 Range

18–41

18–48

18–48

Anaemic at DO

    

 Haematocrit < 30%)

19 (21.8)

21 (24.7)

40 (23.3)

0.396

Height (cm)

    

 Mean ± SD

110.65 ± 21.31

110.65 ± 28.90

110.38 ± 25.36

0.892

 Range

18–143

18–186

18–186